

SPECIALISED COMMISSIONING – RESPONSE TO AMENDMENTS REQUESTED TO EVIDENCE REVIEW DURING ENGAGEMENT OR CONSULTATION

URN	1704
POLICY TITLE	18F-flourodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages)
CRG:	Cancer Diagnostics
NPOC:	Cancer

Description of comments during consultation	<p>Respondents offered papers on tumour margins for radiotherapy relating to one primary study Button MR, Morgan CA, Croydon ES, et al. Study to Determine Adequate Margins in Radiotherapy Planning for Esophageal Carcinoma by Detailing Patterns of Recurrence After Definitive Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; Volume 73 , Issue 3 , 818 – 823</p> <p>Plus response from Muijs CT. et al, and Button, Michael R. et al. Response to Dr. Muijs et al.</p> <p>Also respondents offered papers in support of FDG PET-CT in the staging of oesophageal cancer.</p>
Action taken by Public Health lead	Reviewed Button primary study, which whilst indirectly relevant was outside the scope of the review. Did not review papers on PET-CT in staging oesophageal cancer, as self-evidently outside scope of the review.
Outcome	<u>Not applicable – papers outside the scope of the policy and therefore no additional papers to consider</u>